
Jan 8 (Reuters) - Eli Lilly and Co LLY.N:
LILLY'S TALTZ (IXEKIZUMAB) AND ZEPBOUND (TIRZEPATIDE) USED TOGETHER DELIVERED SUPERIOR EFFICACY IN FIRST-OF-ITS-KIND PHASE 3B TRIAL FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT
ELI LILLY - TOGETHER-PSA STUDY MEETS PRIMARY ENDPOINT WITH 50% PSA IMPROVEMENT
ELI LILLY - TALTZ AND ZEPBOUND DELIVER 64% INCREASE IN ACR50 ACHIEVEMENT
ELI LILLY - ADVERSE EVENTS WITH TALTZ AND ZEPBOUND WERE MILD TO MODERATE
ELI LILLY - TOPLINE RESULTS FROM ONGOING TOGETHER-PSO TRIAL EXPECTED IN H1 2026